Texas patient sues Roche over Raptiva; Amgen wins Sensipar patent case;

@FiercePharma: NYT: Medicare contractor stops Avastin for breast cancer. Item | Follow @FiercePharma 

> Roche's Genentech was sued by a Texas psoriasis sufferer who alleges he developed lymphoma while taking Raptiva, a drug the company stopped selling in 2009 when studies linked it to a fatal brain infection. Report

> Patents on Amgen's kidney drug, Sensipar, have been upheld in a U.S. district court ruling that also barred the sale of generic versions of the drug. News

> Prostrakan has won U.S. approval--although with restrictions--for its cancer pain drug Abstral after repeated delays over safety concerns. Story

> Taking Eli Lilly's Prozac helped stroke patients recover motor skills, according to a study confirming findings that antidepressants may have additional benefits. Report

> Pharmaceuticals marketer Stirling Products is eyeing manufacturing revenues after receiving approval to establish a plant in Canada. Item

> Shares in Smith & Nephew, Europe's largest maker of replacement knees and hips, hit a record high on a report it received an $11 billion bid last month from Johnson & Johnson, which was not disclosed. News

Biotech News

 @FierceBiotech: Frazier: Merck to make "tough" spending decisions. Report | Follow @FierceBiotech

> Astellas mulls sale of subsidiary. Story

> Epizyme lands $650M GSK deal. Article 

> Intermune plots another Phase III for pirfenidone. News

> Sanofi goes back to the negotiation table with Genzyme. Report

> Alkermes spinout Civitas Therapeutics nabs $20M to fuel Parkinson's program. News

> Motavizumab discontinuation could spur deals, progress in RSV arena. Article

Biotech IT News

> Meta-analysis challenges statin use in cardio treatment. News 

> Mannkind on "worst" list for handling of suspect data. Item 

> Framework can unlock volumes of siloed clinical data. Report 

> Validated diabetes model tweaks trial design, therapy. Story 

> iPhone, 3G show potential for trials. News 

> FDA drafts expectations for clinical e-data. Article

And Finally... Drug recalls linked to shipping pallets could lead to trouble for the wood industry, officials said. Report

Suggested Articles

Gilead Sciences has found a new chief financial officer in an appointment that has mergers and acquisitions written all over it.

Pfizer's role as the hero in ramping up production of a chemo drug badly needed by pediatric oncologists is a turnabout for the drugmaker.

Johnson & Johnson is dealing with $2 billion in patent losses in 2019, but has 10 drugs growing at double-digit percentages, executives said Tuesday.